TALPHERA, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
TALPHERA, INC. (TLPH) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2024-03-06
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2022-09-30 was 0.00 shares.
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-09-30 was 0.00 shares.
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-03-31 was 10.08K shares, a 98.18% decline year-over-year.
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-09-30 was 88.49K shares, a 88.86% decline year-over-year.
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2022 was 20.29K shares.
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2015 was 168.34K shares, a 81.19% decline from fiscal 2014.
- TALPHERA, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2014 was 895.19K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | 0.00 shares 10-K · filed 2024-03-06 | ||||
| 2023-09-30 | 0.00 shares 10-Q · filed 2023-11-14 | ||||
| 2022-12-31 | 20.29K shares 10-K · filed 2024-03-06 | ||||
| 2022-09-30 | 0.00 shares 10-Q · filed 2022-11-14 | 5.76K shares 10-Q · filed 2023-11-14 | 27.09K shares 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | 0.00 shares 8-K · filed 2023-08-01 | ||||
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-14 | 0.00 shares 10-Q · filed 2022-11-14 | |||
| 2016-03-31 | 10.08K shares 10-Q · filed 2017-05-08 | ||||
| 2015-12-31 | 168.34K shares 10-K · filed 2018-03-09 | ||||
| 2015-09-30 | 88.49K shares 10-Q · filed 2016-11-02 | 189.66K shares 10-Q · filed 2016-11-02 | |||
| 2015-06-30 | 287.98K shares 10-Q · filed 2016-07-29 | ||||
| 2015-03-31 | 553.35K shares 10-Q · filed 2016-05-02 | ||||
| 2014-12-31 | 895.19K shares 10-K · filed 2017-03-03 | ||||
| 2014-09-30 | 794.14K shares 10-Q · filed 2015-11-03 | 955.95K shares 10-Q · filed 2015-11-03 | |||
| 2014-06-30 | 976.96K shares 10-Q · filed 2014-08-11 | 511.83K shares 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |